Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318276 | 0.92 | SLC6A9 (0.42) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL4332574 | 0.78 | OPRM1 (0.38) | SLC6A9OPRM1OPRL1 | |
| SCHEMBL4322415 | 0.76 | OPRM1 (0.69) | OPRM1OPRL1 | |
| SCHEMBL9963252 | 0.75 | SLC6A9 (0.67) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL4331690 | 0.74 | OPRM1 (0.43) | OPRM1OPRL1 | |
| SCHEMBL4318217 | 0.74 | ADRA1D (0.40) | OPRM1OPRL1 | |
| SCHEMBL9965964 | 0.74 | SLC6A9 (0.64) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL4341092 | 0.73 | OPRL1 (0.41) | OPRM1OPRL1 | |
| SCHEMBL4325606 | 0.73 | OPRM1 (0.35) | OPRM1OPRL1KCNH2 | |
| SCHEMBL4332987 | 0.73 | OPRD1 (0.49) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | SLC6A9 733/4885OPRM1 264/4885SLC6A5 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.